{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:53:50Z","timestamp":1790812430908,"version":"4.1.0"},"reference-count":127,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T00:00:00Z","timestamp":1517961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Disease overview<\/jats:title><jats:p>Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm with an incidence of 1\u20102 cases per 100 000 adults. It accounts for approximately 15% of newly diagnosed cases of leukemia in adults.<\/jats:p><\/jats:sec><jats:sec><jats:title>Diagnosis<\/jats:title><jats:p>CML is characterized by a balanced genetic translocation, t(9;22)(q34;q11.2), involving a fusion of the Abelson gene (<jats:italic>ABL1<\/jats:italic>) from chromosome 9q34 with the breakpoint cluster region (<jats:italic>BCR<\/jats:italic>) gene on chromosome 22q11.2. This rearrangement is known as the Philadelphia chromosome. The molecular consequence of this translocation is the generation of a <jats:italic>BCR\u2010ABL1<\/jats:italic> fusion oncogene, which in turn translates into a BCR\u2010ABL1 oncoprotein.<\/jats:p><jats:p><jats:bold>Frontline therapy<\/jats:bold>: Four tyrosine kinase inhibitors (TKIs), imatinib, nilotinib, dasatinib, and bosutinib are approved by the United States Food and Drug Administration for first\u2010line treatment of patients with newly diagnosed CML in chronic phase (CML\u2010CP). Clinical trials with second generation TKIs reported significantly deeper and faster responses; this has not translated into improved long\u2010term survival, because of the availability of effective salvage therapies.<\/jats:p><jats:p><jats:bold>Salvage therapy<\/jats:bold>: For patients who fail frontline therapy, second\u2010line options include second and third generation TKIs. Second and third generation TKIs, although potent and selective, exhibit unique pharmacological profiles and response patterns relative to different patient and disease characteristics, such as patients\u2019 comorbidities, disease stage, and BCR\u2010ABL1 mutational status. Patients who develop the T315I \u201cgatekeeper\u201d mutation display resistance to all currently available TKIs except ponatinib. Allogeneic stem cell transplantation remains an important therapeutic option for patients with CML\u2010CP who have failed at least 2 TKIs, and for all patients in CML advanced phases.<\/jats:p><\/jats:sec>","DOI":"10.1002\/ajh.25011","type":"journal-article","created":{"date-parts":[[2018,2,7]],"date-time":"2018-02-07T05:25:17Z","timestamp":1517981117000},"page":"442-459","source":"Crossref","is-referenced-by-count":342,"title":["Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring"],"prefix":"10.1002","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[{"name":"Department of Leukemia The University of Texas M. D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[{"name":"Department of Leukemia The University of Texas M. D. Anderson Cancer Center Houston Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,2,7]]},"reference":[{"key":"e_1_2_9_2_1","volume-title":"Cancer Facts & Figures 2017","author":"American Cancer Society","year":"2017"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26679"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V82.6.1838.1838"},{"issue":"11","key":"e_1_2_9_6_1","first-page":"1111","article-title":"Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto\u2010oncogene Raf\u20101","volume":"22","author":"Okuda K","year":"1994","journal-title":"Exp Hematol."},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.25.11746"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90241-4"},{"issue":"2","key":"e_1_2_9_9_1","first-page":"247","article-title":"Constitutive activation of STAT5 by the BCR\u2010ABL oncogene in chronic myelogenous leukemia","volume":"13","author":"Shuai K","year":"1996","journal-title":"Oncogene."},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.3.811"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.49.31704"},{"issue":"5","key":"e_1_2_9_12_1","first-page":"1517","article-title":"An evidence\u2010based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver RT","year":"1999","journal-title":"Blood."},{"key":"e_1_2_9_13_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8\u2010year follow up: sustained survival and low risk for progression of events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2010CP) treated with imatinib","volume":"114","author":"Deininger M","year":"2009","journal-title":"Blood."},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23427"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-110189"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402329"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690230"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI9083"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022457"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24748"},{"key":"e_1_2_9_22_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.630.630","article-title":"India Generic imatinib in chronic myeloid leukemia: survival of the cheapest","volume":"128","author":"Madhav D.","year":"2016","journal-title":"Blood."},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.3724"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004095"},{"key":"e_1_2_9_25_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V130.Suppl_1.897.897","article-title":"Final evaluation of randomized CML\u2010study IV: 10\u2010year survival and evolution of terminal phase","volume":"130","author":"Hehlmann R","year":"2017","journal-title":"Blood."},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm049486a"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-4187"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1099480"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002315"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-02-410688"},{"key":"e_1_2_9_33_1","first-page":"517","article-title":"Spiri6 2: An NCRI randomized study comparing dasatinib with imatinib in patients with newly diagnosed CML","volume":"124","author":"O'Brien SG","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055229"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24423"},{"key":"e_1_2_9_36_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7051","article-title":"Impact of dose reductions on 5\u2010year efficacy in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML\u2010CP) from DASISION","author":"Cortes J","year":"2017","journal-title":"Am Soc Clin Oncol."},{"key":"e_1_2_9_37_1","first-page":"130:","article-title":"Evaluating the role of lower dose dasatinib in newly diagnosed early chronic phase\u2010chronic myeloid leukemia (CML\u2010CP)","author":"Naqvi K","year":"2017","journal-title":"Blood."},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.01.007"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912614"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-09-601674"},{"key":"e_1_2_9_42_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7002","article-title":"Bosutinib versus Iimatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE Trial","author":"Cortes JE","year":"2017","journal-title":"J Clin Oncol."},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00021-6"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0157"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.111.079921"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-09-180604"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24257"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22037"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.04.005"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.22051"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.69"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsb1013826"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.1845"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490003"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr060"},{"key":"e_1_2_9_56_1","first-page":"738","article-title":"What is the most cost\u2010effective strategy for treating newly diagnosed chronic myeloid leukemia (CML) after imatinib loses patent exclusivity?","volume":"124","author":"Larson RA","year":"2014","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.4.789.789"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/90.11.850"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-05-501569"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-229864"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9176"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0598"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6999"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.6565"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-490128"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-11-466037"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.090282"},{"key":"e_1_2_9_68_1","first-page":"254","article-title":"Any BRC\u2010ABL reduction below 10% at 6 months of therapy significantly improves outcome for CML patients with a poor response at 3 months","volume":"122","author":"Branford S","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstracts)."},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0693"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2016.10.006"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(16)30167-3"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.247"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200725060-00004"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-12-196543"},{"key":"e_1_2_9_76_1","unstructured":"Bristol\u2010Myers Squibb Company. Sprycel\u00ae (dasatinib) prescribing information. Princeton NJ;2011."},{"key":"e_1_2_9_77_1","unstructured":"Novartis Pharmaceuticals Corporation. Tasigna\u00ae (nilotinib) prescribing information. East Hanover NJ;2011."},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-154344"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24504"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.3780.3780"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.2765.2765"},{"key":"e_1_2_9_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-05-355594"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V118.21.451.451"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24325"},{"key":"e_1_2_9_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1747-0285.2010.01054.x"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306494"},{"key":"e_1_2_9_88_1","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.7012","article-title":"Five\u2010year results of the ponatinib phase II PACE trial in heavily pretreated CP\u2010CML patients","author":"Kantarjian HM","year":"2017","journal-title":"Am Soc Clin Oncol."},{"key":"e_1_2_9_89_1","volume-title":"Iclusig (Ponatinib) [Prescribing Information]","year":"2014"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702"},{"key":"e_1_2_9_91_1","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.625.625","article-title":"Expanded phase 1 study of ABL001, a potent, allosteric inhibitor of BCR\u2010ABL, reveals significant and durable responses in patients with CML\u2010chronic phase with failure of prior TKI therapy","volume":"128","author":"Hughes TP","year":"2016","journal-title":"Blood."},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-080838"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25717"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-04-214221"},{"key":"e_1_2_9_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.8230"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-07-513937"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.12.005"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-08-302679"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-141689"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.90"},{"key":"e_1_2_9_101_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2014-0218"},{"key":"e_1_2_9_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70233-3"},{"key":"e_1_2_9_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-02-483750"},{"key":"e_1_2_9_104_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-742205"},{"issue":"22","key":"e_1_2_9_105_1","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood.V128.22.787.787","article-title":"Cessation of tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients with deep molecular response: results of the euro\u2010ski trial","volume":"128","author":"Mahon FX","year":"2016","journal-title":"Blood."},{"key":"e_1_2_9_106_1","unstructured":"Duration of deep molecular response has most impact on the success of cessation of tyrosine kinase inhibitor treatment in chronic myeloid leukemia \u2010 results from the EURO\u2010SKI trial.Blood.2017;130: abstract 313."},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24249"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw003"},{"key":"e_1_2_9_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29512"},{"key":"e_1_2_9_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-696013"},{"key":"e_1_2_9_111_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-696013"},{"key":"e_1_2_9_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-336685"},{"key":"e_1_2_9_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.121"},{"key":"e_1_2_9_114_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aag1180"},{"key":"e_1_2_9_115_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1925"},{"key":"e_1_2_9_116_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.10.013"},{"key":"e_1_2_9_117_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-545640"},{"key":"e_1_2_9_118_1","doi-asserted-by":"publisher","DOI":"10.2174\/15680096113139990086"},{"key":"e_1_2_9_119_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.3339"},{"key":"e_1_2_9_120_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-031682"},{"key":"e_1_2_9_121_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019836"},{"key":"e_1_2_9_122_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22778"},{"key":"e_1_2_9_123_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.323"},{"key":"e_1_2_9_124_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-08-2958"},{"key":"e_1_2_9_125_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261586"},{"key":"e_1_2_9_126_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190601075973"},{"key":"e_1_2_9_127_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30864"},{"key":"e_1_2_9_128_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2013.08.008"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.25011","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.25011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:53:01Z","timestamp":1695574381000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.25011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,7]]},"references-count":127,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1002\/ajh.25011"],"URL":"https:\/\/doi.org\/10.1002\/ajh.25011","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,7]]}}}